Miller School of Medicine Dermatologist Co-Authors Groundbreaking Study of Nemolizumab for Itch Relief in NEJM
February 21, 2020
February 21, 2020
MIAMI, Florida, Feb. 21 [TNSmedicalresearch] -- The University of Miami's Miller School of Medicine issued the following news:
A new medication offers hope to patients with prurigo nodularis, a rare nodular skin disease that causes intense itching. "Clinicians need an effective treatment for prurigo nodularis, and a monoclonal antibody called nemolizumab has shown promising results in its initial trials," said Gil Yosipovitch, M.D., director of the Miami Itch Center a . . .
A new medication offers hope to patients with prurigo nodularis, a rare nodular skin disease that causes intense itching. "Clinicians need an effective treatment for prurigo nodularis, and a monoclonal antibody called nemolizumab has shown promising results in its initial trials," said Gil Yosipovitch, M.D., director of the Miami Itch Center a . . .